DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Susoctocog alfa
Susoctocog alfa
Clinical Commissioning Policy: Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia a (All Ages)
Human and Recombinat Coagulation Factor VIII
Annual Report 2016
Therapeutics Advisory Group
Australian Public Assessment Report for Lonoctocog Alfa (Rch)
Dossier Zur Nutzenbewertung Gemäß § 35A SGB V
Australian PI
Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020
A Practical Approach to the Patient with Acquired Haemophilia a in Poland
Treatment of High-Risk Bleeding with Susoctocog Alfa in a Patient with Acquired Haemophilia a and a Nosocomial Severe Acute Resp
Obizur, INN Susoctocog Alfa
Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review
Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
International Recommendations on the Diagnosis and Treatment of Acquired Ferrata Storti Foundation Hemophilia A
Lists of Medicinal Products for Rare Diseases in Europe*
Recombinant Factor VIII: Past, Present and Future of Treatment of Hemophilia A
Final Belgian List
(INN) for Biological and Biotechnological Substances
Top View
PRAC Draft Agenda of Meeting 23-26 November 2020
WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
Prescribing Outlook Includes Such Drugs but Underpinning the Strategic Direction for Managing New Quantifying Their Impact Is Difficult
3-6 July 2017 PRAC Meeting Minutes
ELOCTA, INN-Efmoroctocog Alfa
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England
JAPC Annual Report 2016/2017
Repertorium 2019
CHMP December 2018 Agenda for Publication
(CHMP) Agenda for the Meeting on 21-24 June 2021
Exe Brochure Mds__2018 Versi
APC Monthly Update
Prescription Medicines and Biologicals: TGA Annual Summary 2016 Prescription Medicines and Biologicals: TGA Annual Summary 2016 Contents
Report Template
Obizur, INN Susoctocog Alfa
Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T
CHMP Agenda of the 25-29 January 2021 Meeting
WHO Drug Information Vol
PDCO Minutes of the 25-27 May 2016 Meeting
List Item Minutes of the COMP Meeting 6-8 October 2015 (PDF
TAG Mail – 17 Dec 2020
Final Belgian List
Repertorium 2018
Obizur, INN Susoctocog Alfa
(CHMP) Final Agenda for the Meeting on 25-28 February 2019 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Obizur, INN Susoctocog Alfa
Obizur (Susoctocog Alfa) for the Treatment of Haemophilia A
Cross‐Reacting Inhibitors Against Recombinant Porcine Factor VIII in Acquired Hemophilia A: Data from the GTH‐AH 01/2010 Study
(INN) for Biological and Biotechnological Substances
Scientific Programme Friday, 05. July 2019 Registration
COVID-19 Publications - Week 20 2021 1133 Publications
Scientific Programme Sunday, 12. July 2020 PL 01, Plenary Session Test
Final Minutes CHMP 10-13 December 2018 Publication
NATIONAL INSTITUTE for HEALTH and CARE EXCELLENCE Scope to Inform NHS England's Specialised Commissioning
Thursday 24Thjune 2021 16:00-18:20
List of Medicinal Products Under Additional Monitoring
1908-Liste-Comm.Pdf
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13
Tenofovir Alafenamide
2017/19 Pbr Excluded Drugs: Proposed GMMMG Advisory Position [Appendix 3]
Pbr Excluded Drugs List
Agenda for the Meeting on 22-25 June 2015
Evidence Review of Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia A
PRAC Agenda 08-11 June 2020
Lijst Listing Def V2 .Pdf